Agios Reports Q2 2026, PYRUKYND Net Revenue $44.7M

Agios Pharmaceuticals reported a 3x year-over-year net revenue increase for its mitapivat products in Q2 2026, driven by strong demand in the U.S. and Europe. The company secured an FDA Priority Review for a sickle cell disease indication, expansions into polycythemia vera and Immune Thrombocytopenia (ITP), and posted solid cash position.